Robin Toft Interviewed by WealthChoice: Aiming for the C-Suite? 4 Resources You Need

Your career is what you make it, but developing key relationships can make all the difference in how far you’ll go.

Robin Toft has advised many men and women on their career paths to the C-Suite. While they have all had extensive experience and an impressive resume, additional resources and relationships have played a significant role in their success.

Robin’s interview with WealthChoice outlines these 4 key areas that should be part of your ongoing career development to land a seat at the executive table.

Read Robin’s interview with WealthChoice

Toft Group Completes Executive Search for Retrophin, Inc., (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Dr. Forrest Fuller as Executive Director, Business Development at Retrophin, Inc., in San Diego, CA. He offers 25+ years of early stage biotechnology experience spanning business development, licenses, M&A transactions as well as developing alliances and partnerships. He formerly served with Organovo as their VP of Business Development, where he managed opportunities to leverage Organovo’s 3D Bioprinting technology for value inflection through spinouts, acquisitions and strategic drug discovery alliances. He earned a PhD in Biochemistry and Molecular Biology from Harvard University.

About Retrophin, Inc.

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.

Toft Group Completes Senior Vice President of R&D Search for Dovetail Genomics in Santa Cruz, CA

Dovetail Genomics™ LLC, the industry leader in the use of proximity ligation and advanced informatics for genomic solutions, has appointed Dr. Ramesh Ramakrishnan Senior Vice President of Research and Development. Prior to joining Dovetail, Dr. Ramakrishnan was Executive Vice President of Research and Development at Fluidigm Corp., where he managed the development of single cell genomic and proteomic tools, as well as bulk genomic analysis.

“We are thrilled to welcome Ramesh to the Dovetail team,” said Todd Dickinson, CEO of Dovetail Genomics. “His deep experience in the development and commercialization of genomic products and solutions represents an important addition to the management team as we continue expanding our portfolio. Just as important, he will be responsible for identifying new opportunities to leverage our core expertise, driving the development of exciting new applications in genomics for our customers.”

Robin Toft, President and CEO of Toft Group said: “Dovetail is a forward-thinking organization with an incredibly passionate leadership team. Ramesh will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

Dr. Ramakrishnan brings to Dovetail more than 25 years experience in biotech and clinical research, and in commercialization of genomic solutions. He holds a PhD in Zoology from Georgetown University and the University of Poona, India, which he earned through the Fulbright Scholarship Program. Prior to his tenure at Fluidigm, Dr. Ramakrishnan worked at Nanosphere and Motorola Life Sciences in assay and array development.Robin Toft, President and CEO of Toft Group said: “GeneCentric is a forward-thinking organization with an incredibly passionate leadership team. Walter will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Dovetail Genomics

Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all. The company enables researchers and clinicians to solve complex problems involving de novo assembly, structural variation, microbiome analysis, cancer research, phasing analysis and more by providing them a more comprehensive view of the genome. Its proprietary in vitro proximity ligation approach and assembly algorithms simplify genomic discovery by integrating the highest quality long-range genomic information with next-gen sequencing output. Dovetail is based in Santa Cruz, California.

Toft Group Completes Executive Search for Anatrace, Inc., in Maumee, OH

Executive search firm Toft Group has placed Mr. Mike Irwin as Vice President of Sales at Anatrace, Inc., in Maumee, OH.  Previously, he served with Raindance Technologies as Director of Sales Americas where he drove sales of their RainDrop Plus™ Digital PCR and ThunderStorm® Next-Generation Sequencing Target Enrichment Systems. He earned an MBA from Pepperdine University.

About Anatrace, Inc.

Research facilities, academic institutions, and industrial customers worldwide have trusted Anatrace for high-purity detergents, lipids, customs, and, of course, higher standards since the late 1980s. Well regarded as top performers for membrane protein structural biology, Anatrace products are chosen for their uniquely pure molecules – and the exacting chemistry behind them.

Toft Group Completes Executive Search for Cell Medica, Ltd. in Houston, TX

Executive search firm Toft Group has placed Dr. Luis Borges as Chief Scientific Officer at Cell Medica, Ltd. in Houston, TX. Dr. Borges most recently served at Five Prime Therapeutics as the Senior Vice President, Research, where he assisted in rebuilding the company’s pipeline and re-focusing efforts in cancer immunotherapy. For 12 years prior, he held multiple roles at Amgen, Inc., where his work focused on the development of new immunotherapy approaches to engage different immune cell subsets to eliminate malignant cells. Dr. Borges earned his BS from the University of Lisbon, and his PhD in Pathology for the University of Washington.

About Cell Medica

Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Our lead product is CMD-003 is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. We are working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, we are collaborating with University College London to develop the Dominant TCR technology platform. Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.

Toft Group Completes Executive Search for bioTheranostics in San Diego, CA

Executive search firm Toft Group has placed Ms. Debra Hadley as Vice President of Laboratory Operations at bioTheranostics in San Diego, CA. She offers 30+ years of laboratory operations management, most recently serving as VP of Operations Excellence and Head of Laboratory Operations for Genoptix. She earned an MBA from the University of Phoenix.

About bioTheranostics

bioTheranostics, part of the worldwide bioMérieux group, discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA.

Toft Group Completes Executive Search for Zenith Epigenetics, Ltd. in Calgary, Alberta, Canada

Executive search firm Toft Group has placed Dr. Edward van der Horst as Vice President, Discovery Biology & Pre-Clinical Development at Zenith Epigenetics, Ltd., in Calgary, Alberta, Canada. Dr. van der Horst brings 15 years of experience developing monoclonal antibody therapeutics, target discovery, selection and validation. He previously served at Igenica Biotherapeutics as Senior Director of Preclinical Drug Development. Previous, Dr. van der Horst’s contributions and discoveries at OncoMed Pharmaceuticals as a Senior Scientist have led to the development and clinical evaluation of anti-DLL4 and anti-NOTCH2/3 antibodies, the first clinical stage anti-HER3 antibody at U3 Pharma GmbH. Dr. van der Horst earned his MSc in Chemistry from Ludwig-Maximillians University and his PhD in Biochemistry from Max-Planck Institute for Biochemistry, both located in Munich, Germany.

About Zenith Epigenetics, Ltd.

Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC).

Toft Group Completes Executive Search for Anatrace, Inc., in Maumee, OH

Executive search firm Toft Group has placed Mr. James Schmalz as Head of Operations at Anatrace, Inc., in Maumee, OH. Prior, he served as the Operations Manager and Site Leader for VWR Chemicals, overseeing their chemical manufacturing and distribution facility. He holds an MBA from the University of Akron.

About Anatrace, Inc.

Research facilities, academic institutions, and industrial customers worldwide have trusted Anatrace for high-purity detergents, lipids, customs, and, of course, higher standards since the late 1980s. Well regarded as top performers for membrane protein structural biology, Anatrace products are chosen for their uniquely pure molecules – and the exacting chemistry behind them.

Toft Group Completes Executive Search for ClickDiagnostics in San Jose, CA

Executive search firm Toft Group has placed Mr. Ryan Schmidt as Vice President, Marketing at ClickDiagnostics in San Jose, CA. Mr. Schmidt is a sales and marketing executive specializing in the healthcare industry. He most recently served with Alere, Inc. as Vice President of Marketing, Infectious Diseases. In this role, he successfully launched the Alere™ i Point of Care molecular platform which attained market leadership.. Mr. Schmidt received his BA in Business Communications from Gustavus Adolphus College and MBA in International Business and Marketing at Marquette University.

About ClickDiagnostics

ClickDiagnostics has brought together top-notch technologists, development activists, entrepreneurs, medical professionals and public health practitioners to bring new dimension to addressing the above issues using mobile phones. It is based on the premise that as mobile phone coverage extends to all corners of the world, mobile-phone based health services will become increasingly ubiquitous for connecting different layers of the public health infrastructure and also to collect patient health data and enable remote diagnosis connecting patients to medical professionals, anywhere. Since our incorporation in May 2008, we have been implementing mobile-phone based tele-consultation services in Africa, South Asia, and the Americas, enabling patients to access quality medical treatment in areas where there is little or no access to doctors. At the same time, we have been working with health organizations, governments, and NGOs, to collect real-time health data enabling effective health interventions. With a mobile tele-consultation platform, we also added medical record analysis features enabling doctors to view patient medical history in order to provide appropriate diagnosis and treatment advice.

Toft Group Completes Executive Search for Retrophin (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Andrea Loewen-Rodriguez as Vice President, Regulatory Affairs and Quality Assurance at Retrophin in San Diego, CA. Ms. Loewen-Rodriguez is a global regulatory executive with 20+ years of pharmaceutical industry experience. She previously served at Vital Therapies as Vice President, Regulatory Affairs/ Quality where she was appointed to manage development and execution of U.S., EU, and RoW regulatory strategies. Prior to her role at Vital, Ms. Loewen-Rodriguez served at Shire Pharmaceuticals as Senior Director- Head, Global Regulatory Affairs- Regenerative Medicine. She earned her BA in Biology from Gustavus Adolphus College.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.